Dopaminergic Medicines used in the treatment of Parkinson’s Disease: Risk of Dopamine Dysregulation Syndrome

Dopaminergic Medicines used in the treatment of Parkinson’s Disease: Risk of Dopamine Dysregulation Syndrome

MSD (Pty) Ltd, as directed by the South African Health Products Regulatory (SAHPRA) would like to inform healthcare professionals about the risk of dopamine dysregulation syndrome (DDS) associated with the use of dopamine containing medicines in the treatment of Parkinson’s Disease. The Professional Information (PI) and Patient Leaflet (PIL) for carbidopa and levodopa (SINEMET and SINEMET CRTM) will be amended to reflect this safety issue.

2021 May

Download
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance